LONDON, Nov. 19, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announces its preliminary results for the fourth quarter and the year ended 30 September 2013.
"This was a transformative year for GW with the successful completion of an IPO on NASDAQ, progress with two Phase 3 programs for Sativex in the United States, and the emergence of a new exciting orphan development program in childhood epilepsy," stated Justin Gover, GW's Chief Executive Officer. "We believe that the Company is poised to meet a number of significant clinical, regulatory and commercial milestones for GW investors. These include Phase 3 data from our U.S.-focused pivotal Sativex trials, further Sativex commercial launches and sales growth, progress of the new orphan epilepsy program in the U.S., and further advancement of several other cannabinoid pipeline candidates."
Conference Call and Webcast InformationGW Pharmaceuticals will host a conference call and webcast to discuss the 2013 financial results today at 8:00 a.m. ET / 1:00 p.m. GMT. To participate in the conference call, please dial 877-407-8133 (toll free from the U.S. and Canada), or 0-800-756-3429 (toll free from the UK) or 201-689-8040 (international). Investors may also access a live audio webcast of the call via the investor relations section of the Company's website at http://www.gwpharm.com. A replay of the call will also be available through the GW website shortly after the call and will remain available for 30 days. Replay Numbers: (toll free):1-877-660-6853, (international):1-201-612-7415. For both dial-in numbers please use conference ID # 13572702.
About GW Pharmaceuticals plcFounded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 22 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has established a world leading position in the development of plant-derived cannabinoid therapeutics and has a deep pipeline of additional clinical-stage cannabinoid product candidates targeting epilepsy (including an orphan pediatric epilepsy program), type 2 diabetes, ulcerative colitis, glioma and schizophrenia. For further information, please visit www.gwpharm.com.
Forward-looking statementsThis news release may contain forward-looking statements that reflect GWs current expectations regarding future events, including statements regarding financial performance, timing of clinical trials and data, relevance of GW products commercially available and in development, size of market opportunities, and development and regulatory clearance of GW's products. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of the GW's research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex® and other products by consumer and medical professionals. A further list and description of risks, uncertainties and other risks associated with an investment in GW can be found in GW's filings with the U.S. Securities and Exchange Commission, including the prospectus related to the NASDAQ offering filed by GW with the SEC on May 1, 2013. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. GW Pharmaceuticals plc
Consolidated income statement
For the year ended 30 September 2013Year endedYear endedYear ended30 September30 September30 SeptemberNotes
44,15827,29533,120Cost of sales(2,064)(1,276)(839)Research and development expenditure
(52,897)(32,697)(27,578)Management and administrative expenses(6,135)(3,792)(3,660)Operating (loss)/profit(16,938)(10,470)1,043Interest expense(104)(64)(1)Interest income288178200(Loss)/profit before tax(16,754)(10,356)1,242Tax
9,3955,8071,248(Loss)/profit for the year(7,359)(4,549)2,490(Loss)/earnings per share- basic7
(4.9)c(3.0)p1.8pAll activities relate to continuing operations.
The Group has no gains or losses other than those shown above and therefore no separate statement of recognised income and expense has been presented.GW Pharmaceuticals plc
Consolidated income statement
For the three months ended 30 September 2013Three months
endedThree months endedThree months
ended30 September30 September30 September201320132012$000's£000's£000'sRevenue11,5217,1217,587Cost of sales(567)(351)(302)Research and development expenditure(14,827)(9,165)(9,182)Management and administrative expenses(1,684)(1,041)(693)Operating loss(5,557)(3,436)(2,590)Interest payable(31)(19)-Interest income1086759Loss on ordinary activities before taxation(5,480)(3,388)(2,531)Tax credit on ordinary activities1,191736320Loss on ordinary activities after taxation(4,289)(2,652)(2,211)Loss per share- basic(2.4)c(1.5)p(1.7)p- diluted(2.4)c(1.5)p(1.7)p GW Pharmaceuticals plc
Consolidated balance sheet
As at 30 September 201330 September30 September30 SeptemberNotes
201320132012$000's£000's£000'sNon-current assetsIntangible assets - goodwill8,4295,2105,210Property, plant & equipment8,8595,4762,43217,28810,6867,642Current assetsInventories
7,5414,6613,537Deferred tax asset1,447895–Taxation recoverable4,6922,900820Trade and other receivables
2,8041,7331,588Cash and cash equivalents61,58838,06929,33578,07248,25835,280Total assets95,36058,94442,922Current liabilitiesTrade and other payables
(15,272)(9,440)(9,114)Obligations under finance leases
(5,146)(3,181)(2,449)(20,580)(12,721)(11,563)Non-current liabilitiesObligations under finance leases
(14,424)(8,916)(10,127)Total liabilities(17,506)(23,542)(21,690)Net assets57,27435,40221,232EquityShare capital
288178133Share premium account135,90384,00565,947Other reserves32,65420,18420,184Retained earnings (111,571)(68,965)(65,032)Shareholders' funds57,27435,40221,232This announcement was approved by the Board of Directors on 18 November 2013.GW Pharmaceuticals plc
Consolidated cash flow statement
For the year ended 30 September 2013Year endedYear endedYear ended30 September30 September30 September201320132012$000's£000's£000's(Loss)/profit for the year(7,359)(4,549)2,490Adjustments for:Interest expense
(9,395)(5,807)(1,248)Depreciation of property, plant and equipment
1,600989754Net foreign exchange (gains) / losses
(40)(25)(202)(Decrease)/increase in allowance for doubtful debts
(42)(26)26Decrease in inventory provision
(857)(530)(1,300)Share-based payment charge
9976161,009(15,280)(9,446)1,330Increase in inventories
(961)(594)(813)(Increase) / decrease in trade receivables and other assets
(175)(108)609(Decrease) / increase in trade and other payables and deferred revenue
(246)(152)247Cash (used in)/generated by operations(16,662)(10,300)1,373Research and development tax credits received
4,5822,832428Net cash (outflow)/inflow from operating activities(12,080)(7,468)1,801Investment activitiesInterest received
270167258Purchases of property, plant and equipment
(3,629)(2,243)(1,318)Net cash outflow from investing activities(3,359)(2,076)(1,060)Financing activitiesProceeds on exercise of share options
5381Proceeds of new equity issue
31,98419,770–Expenses of new equity issue
(104)(64)(1)Proceeds from finance leases
364225–Capital element of finance leases
(18)(11)(7)Net cash from financing activities29,52918,25373Effect of foreign exchange rate changes
4025202Net increase in cash and cash equivalents14,1308,7341,016Cash and cash equivalents at beginning of year
47,45829,33528,319Cash and cash equivalents at end of year61,58838,06929,335
|SOURCE GW Pharmaceuticals plc|
Copyright©2012 PR Newswire.
All rights reserved